Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Inclusion Criteria: * Male and female adults 18 to 70 years of age (inclusive) at the time of informed consent. * Diagnosed with mild to moderate AD. * History of AD for at least 6 months as determined by the Investigator through patient interview. * Stable disease for the 4 weeks prior to the screening visit with no significant flares in AD as determined by the Investigator. * Validated Investigator Global Assessment-atopic dermatitis (vIGA-AD) score of Moderate or Mild at Screening. The vIGA-AD was evaluated for the entire body except scalp, palms, soles and genitals. * HadAD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and no more than 14.0% BSA. * Had at least two target lesions 100 cm2 or greater with a difference no greater than 1 point in lesion TSS and at least 5 cm apart located on the trunk (excluding genitals) or upper extremities (excluding palms). * If female, patients with child-bearing potential must have a negative pregnancy test, and agree to practice true abstinence or agree to use highly effective contraception. * If male, agree to use a male condom and highly effective contraception with female partners of child-bearing potential. * In good health as judged by the Investigator. Exclusion Criteria: * Patients who had failed 2 or more prior systemic treatments for AD. * Patients who had received a live or attenuated vaccine in the last 12 weeks or intend to receive a live or attenuated vaccine during the study. * Patients …